Prof. Nick James ‘New Developments in the management of low volume CNPC’
Professor Nick James was also guest speaker on the DUOS Jaarsymposium 2015 en 2017 (Stampede).
Professor James has degrees in medicine and immunology from the University of London and a PhD from Imperial college in cell cycle biology. He undertook postgraduate training in London, Brussels and Tokyo and is a Fellow of the Royal Colleges of Radiology and Physicians.
His work focuses on evaluating and improving clinical trials to achieve better patient outcomes. He evaluates new treatment approaches to both bladder and prostate cancers via large multi-centre clinical trials and actively collaborates with laboratory groups to explore the underlying mechanisms at play in trials.
‘Clinical trials are the ultimate means of translating scientific advances into real gains in patient survival, or improvements in related outcomes such as prevention of unpleasant complications.They require collaboration of many (often thousands) of participants, both as patients and in the clinical teams recruiting and managing the studies. Good design is thus key for optimising the conduct of trials to maximise return on investment,’ says Nick James.
Prof. Alison Birtle ‘Adjuvant chemotherapy in upper and lower tract UCC’
Prof. Alison Birtle Adjuvant chemotherapy in upper and lower tract UCC. Dr Alison Birtle is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre, Preston.
Dr Birtle’s specialist interests cover chemotherapy for urological tumours, targeted therapy and radiotherapy developments. She trained in London at Charing Cross and Westminister Medical School and as a specialist registrar in clinical oncology in North Thames. She completed her MD Thesis at the Institute of Urology, University College London, in PSA negative prostate cancer and finished site specialised training at the Academic Urology Unit, Royal Marsden Hospital.
In November 2007, Dr Birtle was appointed ‘Honorary Clinical Senior Lecturer’ at The University of Manchester in recognition of her academic and clinical research of cancer.
She was Clinical Lead for Research for Lancs & South Cumbria Cancer Research Network until April 2014 and is a member of the Research and innovation Committee at Lancs Teaching Hospitals NHS Foundation Trust and an active member of the Cancer Research Partnership Group.
Dr Birtle is committee member of the British Uro-Oncology Group and Trustee of the Action on Bladder cancer.